Drug
Ker 065
Ker 065: highest development phase Phase 2, developed by Keros Therapeutics, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Keros Therapeutics, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| KER-065 NCT07704099 | Phase 2 | Duchenne Muscular Dystrophy |
Latest
No recent events.
Follow Ker 065 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.